Neoplasms

Blood and Lymph Conditions

All Conditions

Rare Diseases

Thymoma

Thymus Neoplasms

Neoplasms by Histologic Type

Thoracic Neoplasms

Lymphatic Diseases

Thymic Epithelial Tumor

With each histopathological type of thymic epithelial tumors, we measure the maximun diameter in chest CT scan. Comparison of some characteristics of the tumor on preoperative chest CT scans and histopathological type of thymic epithelial tumors .

Cross-sectional descriptive study on 53 patients with diagnosed of thymoma by CT and had postoperative histopathology results as thymic epithelial tumors. Base on the characteristics in Chest CT scan in each postoperative histopathology results.

CT and histopathological classification

Truong Giang Nguyen, PhD

the World Health Organization (WHO) has proposed a classification of histopathological thymic tumor and it significance in prognosis. Chest computed tomography (CT) is the most common method to evaluate thymic epithelial tumors before operation. Therefore, the question is to predict the histopathological type of thymic epithelial tumors before surgery based on CT-scan images , to help determine treatment strategy and prognosis. In Vietnam, there are no published literature on this issue.

1. Introduction: the World Health Organization (WHO) has proposed a classification of histopathological thymic tumor and it significance in prognosis. Chest computed tomography (CT) is the most common method to evaluate thymic epithelial tumors before operation. Therefore, the question is to predict the histopathological type of thymic epithelial tumors before surgery based on CT-scan images , to help determine treatment strategy and prognosis. In Vietnam, there are no published literature on this issue.
2. Materials and methods:

   2.1. Cross-sectional descriptive study on 53 patients with diagnosed of thymoma by CT and had postoperative histopathology results as thymic epithelial tumors

   2.2. Time and Place: in Departement of CTVS, Military Hospital 103, Vietnam from 10/2013 to 7/2017.

   2.3. methods:
   * study in chest CT scan:

     * Measure the maximun diameter of the tumor
     * The contour: smooth contour or irregular contour
     * The shape: round, oval and plaque base on the ratio between long axis and short axis of the tumor
     * Some other characteristics: Degree of enhancement, Level of drug absorbed, Calcification, Invasion the local organs and Capsular destruction.
   * Histopathological study: based on the 2004 WHO classification:

     * Thymoma: type A, AB, B1, B2, B3
     * Thymic carcinoma
   * Data processing: use software Epi Info 2000.
3. Expectation of results

   * Relationship between the size and histopathological type of thymic epithelial tumors.
   * Comparison of some characteristics of the tumor on preoperative chest CT scans and histopathological type of thymic epithelial tumors

Cross-sectional descriptive study on 53 patients with diagnosed of thymoma by CT and had postoperative histopathology results as thymic epithelial tumors

Relationship Between Computed Tomography Manifestation and Histopathological Classification of Thymic Epithelial Tumors

Evaluate the Relationship Between Computed Tomography Manifestation and Histopathological Classification of Thymic Epithelial Tumors

Measure the maximun diameter of the tumor in chest CT scan

Nguyen Truong Giang

Military Hospital 103

Principal Investigator

Neoplasms, Glandular and Epithelial

Antineoplastic Agents

All Drugs and Chemicals

Pembrolizumab

Cisplatin

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Pembrolizumab 200mg IV every 3 weeks until tumor progression or unacceptable toxicity

treated with Pembrolizumab 200 mg every 3 weeks

Myung-Ju Ahn, Prof.

This is a Phase II single center, open-label, single arm study in patients with advanced thymic epithelial tumors after failure of cisplatin-based combination chemotherapy. Patients will be treated with Pembrolizumab 200 mg every 3 weeks.

A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor

A Phase II Study of Pembrolizumab for Patients With Thymic Epithelial Tumor Who Progressed After at Least One Previous Regimen of Cisplatin-Containing Chemotherapy

complete response plus partial response as determined by RECIST 1.1

time from the on-study date to date of disease progression

time from the on-study date to death as a result of any cause

Samsung Medical Center

Professor

Respiratory Tract (Lung and Bronchial) Diseases

Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Small Cell

Lung Neoplasms

Neuroendocrine Tumors

Carcinoma

Respiratory Tract Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Small Cell Lung Cancer

Neuroendocrine Tumor

Neuroepithelioma

Patients with histologically or cytologically confirmed NSCLC, SCLC, ESCC, PNET, and TET

Shannon G Swift, R.N.

Arun Rajan, M.D.

For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

Background:

- Lung cancer is the leading cause of cancer-related death worldwide. It causes more than one million deaths every year. Researchers want to gather tissue samples from people with lung and thymic cancers to understand the disease better. This may lead to new ways to diagnose and treat it.

Objective:

- To collect tissue samples for use in the study of lung cancers.

Eligibility:

- Adults over age 18 with non-small cell lung cancer, small cell lung cancer, extra pulmonary small cell cancer, pulmonary neuroendocrine tumors, and thymic epithelial tumors.

Design:

* Participants will be screened with a medical history, physical exam, and blood tests. They will be asked about how they perform their daily tasks.
* Participants may be asked to give urine and blood samples. They may give a saliva sample if they cannot give blood. They will also give a sample of their tumor from a biopsy they had. They may also be given the option to undergo a biopsy.
* Participants may have MRI, CT, and/or PET scans of the body. They will lie in a machine that takes pictures of the body.
* After visits to the Clinical Center end, researchers will contact participants by phone every year to check on their health.

Background:

* Lung cancer is the leading cause of cancer-related death worldwide, accounting for more than one million deaths every year.
* Several genetic and epigenetic alterations are involved in initiation and progression of NSCLC. Some of these alterations are seen in normal and preneoplastic cells as well, suggesting a sequential development from normal epithelial cells to cancer, through a multistep process, usually coincident with cigarette smoking.
* This natural history protocol is an extension of our Molecular Profiling protocol to enable tissue collection for more in-depth proteomic and genomic analyses to understand tumor biology and treatment response.
* A cohort of patients enrolled in this natural history study is likely to enroll in the IRB approved protocol for end-of-life in-patient hospice and rapid autopsy following death (13-C0131). Longitudinally collected tumor tissue from these patients, including from several metastatic sites at autopsy will be a unique resource to understand tumor evolution.
* There will be opportunity to embark upon a wide array of studies in the future with the longitudinally collected tissue samples tagged with clinical information from patients.

Objectives:

- To allow sample acquisition for use in the study of non-small cell lung cancer (NSCLC), Small cell lung cancer (SCLC), extrapulmonary small cell cancer (ESCC), pulmonary neuroendocrine tumors (PNET), and thymic epithelial tumors (TETs).

Eligibility:

* Patients with histologically or cytologically confirmed NSCLC, SCLC, ESCC, PNET, and TET.
* Patients consulted in the Clinical Center without a definitive diagnosis, but clinically considered likely to have a thoracic malignancy of the above histologies, pending further tissue acquisition and/or pathology review.
* Age greater than or equal to 18 years.

Design:

* This is a bio-specimen collection and natural history protocol in which samples will be collected from patients with NSCLC, SCLC, ESCC, PNET, and TET.
* Eligible patients undergoing screening for or participating in NIH protocols or eligible patients treated elsewhere and referred from other oncologists will be referred for participation in this study.
* Upon providing informed consent, patients will undergo sample acquisition procedures, which may include a tumor biopsy, bone marrow biopsy or the collection of blood, urine or other body fluids.
* An accrual ceiling of 2000 subjects is planned over an accrual period of 10 years.

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

Tissue Procurement and Natural History Study of Patients With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

.All IPD recorded in the medical record will be shared with intramural investigators upon request. In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP.

blood, tumor, body fluids, and normal tissue samples

clinical data, including overall survival

Specific studies include, but not limited to genomic analyses using NGS technologies (exome, transcriptome and/or whole genome sequencing), DNA methylation analyses, DNA copy number analyses, proteomic studies including mass spectrometry, capillary Westerns, reverse phase protein microarrays (RPPA), luminex assays, ELISA and IHC, and metabolomics studies using mass spectrometry.

National Cancer Institute (NCI)

single arm for all patients tumor samples will be taken for RNA sequencing of epithelial tumour cells during surgery.

blood samples will be taken for Exome Sequencing (WES) at baseline, during surgery and one month post surgery.

* tumor samples will be taken for RNA sequencing of epithelial tumour cells during surgery.
* blood samples will be taken for Exome Sequencing (WES) at baseline, during surgery and one month post surgery.

single arm for all patients

Clémence BASSE, MD

Clémence Basse, MD

Agathe SEGUIN, MD

Agathe SEGUIN

Edouard SAGE, MD

The IMMUNO-TET trial aims to assess the feasibility of characterising the immune environment of TETs and the constitutional and somatic molecular profiles of patients with localised thymic epithelial tumour (TET).

In this prospective study, patients undergoing thymectomy and thymomectomy as part of routine care undergo the following care pathway:

1. During the pre-surgical visit (for n = 50 patients): as part of routine care, a blood sample is collected for analysis of CBC, leukocytes, lymphocytes, CRP, ferritinemia, TSH, T3L, T4L, anti-acetycholine receptor antibodies, ...CMV, EBV, HSV, HIV serologies, ...and HLA class I and class II typing.
2. During thymectomy and thymomectomy surgery, the following samples are taken (for n = 50 patients):

   * 6 blood samples on EDTA tubes are collected at the time of surgery for analyses.
   * 3 fresh samples of the surgical specimen are taken by the pathologist: tumour T, juxta-tumour J and distant D locations for analyses by flow cytometry and RNA sequencing. Anatomopathology blocks/slides are also cut in the same way (tumour T, juxta-tumour J and distant D locations) for additional exploratory analyses.
   * The feasibility of developing patient-derived xenografts (PDX) from TETs will be tested for n = 20 tumor samples. These models will allow to test potential therapeutic agents for this pathology.
3. During the 1st month (+/- 7 days) post-surgery check-up, a blood sample is taken again (for n = 50 patients) for routine care: CBC, leukocytes, lymphocytes, CRP, ferritinemia, anti-acetycholine receptor antibodies and for peripheral immune system analysis at a distance from surgery and for constitutional molecular analysis.

Informed consent is given to participate in this prospective study.

Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs)

Sponsor will share de-identified data sets. Documents generated under the project will be disseminated in accordance with Institut Curie policies.

description of genetic abnormalities in thymic tumours compared to non-tumourous thymic tissue (Whole Exome Sequencing RNA-sequencing technique, DNA Optical mapping);

description of immune cells in the tumour environment, description of tumour infiltrating T cells

Molecular constitutional characterisation of TETs with the technique of theExome Sequencing (WES) on blood samples of patients with TETs

WES data analysis constitutional genetic alterations will be performed.

Molecular analyses will be performed to identify potential alterations in signalling pathways that can be targeted by new therapies.

Analysis of TETs single-cell RNA-seq data will be performed.

Transcriptome sequencing analysis will be performed.

Epigenetic characterisation of TETs will be performed by molecular analyses.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Relationship Between Computed Tomography Manifestation and Histopathological Classification of Thymic Epithelial Tumors	NCT03288662	Thymoma	CT and histopat...	21 Years - 71 Years	Military Hospital 103
A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor	NCT02607631	Thymic Epitheli...	Pembrolizumab	18 Years -	Samsung Medical Center
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors	NCT02146170	Non-Small Cell ... Small Cell Lung... Extrapulmonary ... Pulmonary Neuro... Thymic Epitheli...		18 Years -	National Institutes of Health Clinical Center (CC)
Relationship Between Computed Tomography Manifestation and Histopathological Classification of Thymic Epithelial Tumors	NCT03288662	Thymoma	CT and histopat...	21 Years - 71 Years	Military Hospital 103
Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs)	NCT05558644	Cancer	single arm for ...	18 Years -	Institut Curie
Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs)	NCT05558644	Cancer	single arm for ...	18 Years -	Institut Curie
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors	NCT02146170	Non-Small Cell ... Small Cell Lung... Extrapulmonary ... Pulmonary Neuro... Thymic Epitheli...		18 Years -	National Institutes of Health Clinical Center (CC)

Spots Global Cancer Trial Database for thymic epithelial tumors